There are 3 isoforms of apolipoprotein E (apo E) in humans (ε2, ε3, and ε4). Lp(a) contains a highly polymorphic signature protein, apolipoprotein(a) [apo(a)], bound to the apolipoprotein B100 (apo B100) of an LDL particle.
The proatherogenic properties of Lp(a) are mediated by its LDL moiety rich in cholesterol, as well as by its elevated content in proinflammatory oxidized phospholipids, and by the antifibrinolytic effects of its plasminogen-like apo(a) moiety. Elevated Lp(a) is an independent predictor of cardiovascular disease (CVD), particularly for patients with familial hypercholesterolemia (FH) (2, 3) .
To evaluate whether the modulation of Lp(a) levels by apo E isoforms affects CVD risk, we assessed apo E and apo(a) concentrations, as well as polymorphisms, in a cohort of patients at very high cardiovascular risk by liquid chromatography-tandem mass spectrometry The majority of these patients were ε3/ε3 carriers (n ¼ 292) and served as the control group carriers. The remaining patients were ε3/ε4 (n ¼ 79), ε2/ε3 (n ¼ 42),
carriers were excluded from all subsequent analyses.
Compared with ε3/ε3, ε2 carriers (i.e., ε2/ε3 and ε2/ε2) had increased plasma apo E levels, whereas ε4 carriers (i.e., ε3/ε4 and ε4/ε4) had reduced plasma apo E levels These results are unique in that we investigated patients at very high cardiovascular risk, and none of these patients were taking lipid-lowering medication at the time of their first visit (5), we were able to demonstrate that apo E 2 confers a significant degree of cardioprotection. Unlike non-FH subjects, who have variable effects of apo E genotypes on LDL cholesterol (1), apo E 2 did not significantly reduce LDL in our FH cohort, thus indicating that the cardioprotection observed here stems, at least in part, from the lowering of Lp(a).
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There are some limitations to our study, in particular the lack of data on the ethnic background of our patients. However, our results clearly underpin that Lp(a) should be measured systematically in all patients with FH, given that with progressively more effective pharmacological LDL reduction, Lp(a) becomes a strong predictor of CVD (3) and, as such, an important driver of residual CVD risk.
Valentin Blanchard, BS Mikaël Croyal, PhD Plasma apolipoprotein E (apo E) and apolipoprotein(a) levels were measured by liquid chromatography-tandem mass spectrometry in plasma samples isolated from 444 nontreated patients with familial hypercholesterolemia (FH). Plasma low-density lipoprotein (LDL) cholesterol levels were calculated using the Friedewald formula when triglycerides levels were lower than 4.52 mmol/l (i.e., in 440 patients). Apolipoprotein E and low-density lipoprotein cholesterol are displayed as mean AE SEM, and comparisons between groups were made using Student's t-test. Lipoprotein(a) levels are displayed as median (interquartile range), and comparisons between groups were made using a
Wilcoxon rank sum test. Cardiovascular disease (CVD)-free survivals were determined using a Kaplan-Meier estimate. Cumulative hazards for age (probability for a patient to experience a cardiovascular [CV] event or death) were compared using a log-rank test. CI ¼ confidence interval. 
